Amgen Inc. v. Watson Laboratories, Inc.

Application Number	Patent Number	External Links
-	US9375405	Espacenet Google Patents

COMPLAINT for PATENT INFRINGEMENT filed against Actavis Pharma, Inc., Actavis, Inc., Watson Laboratories, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2000856.) - filed by Amgen Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(nmg) (Entered: 09/23/2016)

2016-09-22

1

View

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) (Entered: 09/23/2016)

2016-09-22

1

View

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/11/2016. Date of Expiration of Patent: 9/22/2026. (nmg) (Entered: 09/23/2016)

2016-09-22

1

View

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,375,405 B2. (nmg) (Entered: 09/23/2016)

2016-09-22

1

View

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Amgen Inc. (nmg) (Entered: 09/23/2016)

2016-09-22

1

View

Summons Issued with Magistrate Consent Notice attached as to Actavis Pharma, Inc., Actavis, Inc., Watson Laboratories, Inc.. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (aah)

2016-09-23

1

No Actions

Summons Issued

2016-09-23

1

No Actions

SUMMONS Returned Executed by Amgen Inc.. Actavis Pharma, Inc. served on 9/28/2016, answer due 10/19/2016. (Noreika, Maryellen) (Entered: 09/28/2016)

2016-09-28

1

View

Case Assigned to Judge Gregory M. Sleet. Please include the initials of the Judge (GMS) after the case number on all documents filed. Associated Cases: 1:16-cv-00853-GMS, 1:16-cv-00854-GMS, 1:16-cv-00855-GMS (rjb)

2016-09-28

1

No Actions

Case Assigned/Reassigned

2016-09-28

1

No Actions

DECLARATION of Mailing (as to service on Waston Laboratories, Inc. and Actavis, Inc.) by Amgen Inc.. (Attachments: # 1 Exhibit A - D)(Noreika, Maryellen) Modified on 10/5/2016 (mdb). (Entered: 10/05/2016)

2016-10-05

1

View

STIPULATION TO EXTEND TIME (and proposed order) to move, plead or otherwise respond to the Complaint to November 18, 2016 - filed by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Keller, Karen) (Entered: 10/18/2016)

2016-10-18

1

View

SO ORDERED - re 8 STIPULATION TO EXTEND TIME (and proposed order) to move, plead or otherwise respond to the Complaint to November 18, 2016 filed by Actavis Pharma, Inc., Watson Laboratories, Inc., Set/Reset Answer Deadlines: Actavis Pharma, Inc. answer due 11/18/2016; Watson Laboratories, Inc. answer due 11/18/2016. Ordered by Judge Gregory M. Sleet on 10/20/2016. (mdb)

2016-10-20

1

No Actions

~Util - Set/Reset Answer Deadline AND SO ORDERED

2016-10-20

1

No Actions

MOTION for Pro Hac Vice Appearance of Attorney John W. Bateman, C. Kyle Musgrove, and Elizabeth M. Crompton - filed by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Keller, Karen) (Entered: 10/31/2016)

2016-10-31

1

View

SO ORDERED - re 9 MOTION for Pro Hac Vice Appearance of Attorney John W. Bateman, C. Kyle Musgrove, and Elizabeth M. Crompton filed by Actavis Pharma, Inc., Watson Laboratories, Inc. Ordered by Judge Gregory M. Sleet on 11/3/2016. (mdb)

2016-11-03

1

No Actions

SO ORDERED

2016-11-03

1

No Actions

Pro Hac Vice Attorney Elizabeth M. Crompton for Watson Laboratories, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lmm)

2016-11-04

1

No Actions

Add Attorneys - PHV only

2016-11-04

1

No Actions

MOTION for Pro Hac Vice Appearance of Attorney John D. Murnane, Joshua I. Rothman and Alicia A. Russo of FITZPATRICK, CELLA, HARPER & SCINTO - filed by Amgen Inc.. (Noreika, Maryellen) (Entered: 11/07/2016)

2016-11-07

1

View

Pro Hac Vice Attorney John W. Bateman for Watson Laboratories, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lmm)

2016-11-08

1

No Actions

Add Attorneys - PHV only

2016-11-08

1

No Actions

MOTION for Pro Hac Vice Appearance of Attorney Lois M. Kwasigroch and Wendy A. Whiteford - filed by Amgen Inc.. (Noreika, Maryellen) (Entered: 11/09/2016)

2016-11-09

1

View

SO ORDERED - re (10 in 1:16-cv-00855-GMS, 10 in 1:16-cv-00928-GMS, 8 in 1:16-cv-00853-GMS, 11 in 1:16-cv-00881-GMS, 9 in 1:16-cv-00899-GMS, 10 in 1:16-cv-00925-GMS, 15 in 1:16-cv-00854-GMS, 13 in 1:16-cv-00900-GMS, 14 in 1:16-cv-00880-GMS, 11 in 1:16-cv-00926-GMS, 8 in 1:16-cv-00927-GMS, 12 in 1:16-cv-00882-GMS) MOTION for Pro Hac Vice Appearance of Attorney John D. Murnane, Joshua I. Rothman and Alicia A. Russo of FITZPATRICK, CELLA, HARPER & SCINTO filed by Amgen Inc. Ordered by Judge Gregory M. Sleet on 11/9/2016. Associated Cases: 1:16-cv-00854-GMS et al.(mdb)

2016-11-09

1

No Actions

SO ORDERED

2016-11-09

1

No Actions

STIPULATION of Dismissal of Actavis, Inc., Without Prejudice by Actavis Pharma, Inc., Actavis, Inc., Watson Laboratories, Inc.. (Keller, Karen) Modified on 11/15/2016 (mdb). (Entered: 11/15/2016)

2016-11-15

1

View

SO ORDERED - re (13 in 1:16-cv-00882-GMS, 12 in 1:16-cv-00926-GMS, 11 in 1:16-cv-00928-GMS, 9 in 1:16-cv-00927-GMS, 15 in 1:16-cv-00880-GMS, 16 in 1:16-cv-00854-GMS, 11 in 1:16-cv-00855-GMS, 14 in 1:16-cv-00900-GMS, 11 in 1:16-cv-00925-GMS, 12 in 1:16-cv-00881-GMS, 9 in 1:16-cv-00853-GMS) MOTION for Pro Hac Vice Appearance of Attorney Lois M. Kwasigroch and Wendy A. Whiteford filed by Amgen Inc. Ordered by Judge Gregory M. Sleet on 11/15/2016. Associated Cases: 1:16-cv-00853-GMS et al.(mdb)

2016-11-15

1

No Actions

Pro Hac Vice Attorney Cecil Kyle Musgrove for Watson Laboratories, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lmm)

2016-11-15

1

No Actions

SO ORDERED

2016-11-15

1

No Actions

Add Attorneys - PHV only

2016-11-15

1

No Actions

SO ORDERED - re 12 Stipulation of Dismissal of Actavis, Inc., Without Prejudice. Signed by Judge Gregory M. Sleet on 11/17/2016. (mdb) (Entered: 11/17/2016)

2016-11-17

1

View

ANSWER to 1 Complaint, Counterclaims against Amgen Inc. by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Attachments: # 1 Exhibit A)(Keller, Karen) Modified on 11/18/2016 (mdb). (Entered: 11/18/2016)

2016-11-18

1

View

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceuticals USA Inc., Other Affiliate Teva Pharmaceutical Industries Ltd for Actavis Pharma, Inc., Watson Laboratories, Inc. filed by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Keller, Karen) (Entered: 11/18/2016)

2016-11-18

1

View

ORDER REGARDING CASE MANAGEMENT IN CIVIL CASES. Signed by Judge Gregory M. Sleet on 11/18/2016. (asw) (Entered: 11/18/2016)

2016-11-18

1

View

STIPULATION TO EXTEND TIME for the parties to submit the joint status report and proposed scheduling order to December 15, 2016 - filed by Amgen Inc.. (Blumenfeld, Jack) (Entered: 12/08/2016)

2016-12-08

1

View

Amended ANSWER to 1 Complaint, Answer and Counterclaims 14, COUNTERCLAIM against Amgen Inc. by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Attachments: # 1 Exhibit A)(Keller, Karen) (Entered: 12/09/2016)

2016-12-09

1

View

SO ORDERED - re (15 in 1:16-cv-00928-GMS, 17 in 1:16-cv-00855-GMS, 16 in 1:16-cv-00899-GMS, 16 in 1:16-cv-00925-GMS, 13 in 1:16-cv-00853-GMS, 19 in 1:16-cv-00881-GMS, 19 in 1:16-cv-00854-GMS, 17 in 1:16-cv-00900-GMS, 20 in 1:16-cv-00882-GMS, 19 in 1:16-cv-00880-GMS, 16 in 1:16-cv-00926-GMS, 15 in 1:16-cv-00927-GMS) STIPULATION TO EXTEND TIME for the parties to submit the joint status report and proposed scheduling order to December 15, 2016 filed by Amgen Inc. Ordered by Judge Gregory M. Sleet on 12/12/2016. Associated Cases: 1:16-cv-00854-GMS et al.(mdb)

2016-12-12

1

No Actions

SO ORDERED

2016-12-12

1

No Actions

Joint STATUS REPORT by Amgen Inc.. (Noreika, Maryellen) (Entered: 12/15/2016)

2016-12-15

1

View

ANSWER to 18 Answer to Complaint, Counterclaim -- Plaintiff's Answer to Defendant Watson Laboratories, Inc.'s Amended Counterclaims -- by Amgen Inc..(Blumenfeld, Jack) (Entered: 12/27/2016)

2016-12-27

1

View

NOTICE OF SERVICE of Defendants First Set of Requests for Production filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Matterer, Mary) (Entered: 01/05/2017)

2017-01-05

1

View

STIPULATION TO EXTEND TIME to serve Initial Disclosures Puruant to Fed. R. Civ. P. 26(a) and Pursuant to Paragrah 3 of Default Standard for Discovery to January 13, 2017 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Matterer, Mary) (Entered: 01/06/2017)

2017-01-06

1

View

NOTICE OF SERVICE of Plaintiff's Default Standard 4(a) Disclosures filed by Amgen Inc..(Blumenfeld, Jack) (Entered: 01/06/2017)

2017-01-06

1

View

SO ORDERED - re (24 in 1:16-cv-00854-GMS, 20 in 1:16-cv-00927-GMS, 22 in 1:16-cv-00900-GMS, 26 in 1:16-cv-00882-GMS, 19 in 1:16-cv-00853-GMS, 23 in 1:16-cv-00881-GMS, 22 in 1:16-cv-00855-GMS, 24 in 1:16-cv-00899-GMS, 20 in 1:16-cv-00928-GMS, 23 in 1:16-cv-00880-GMS, 21 in 1:16-cv-00926-GMS, 21 in 1:16-cv-00925-GMS) STIPULATION TO EXTEND TIME to serve Initial Disclosures Puruant to Fed. R. Civ. P. 26(a) and Pursuant to Paragrah 3 of Default Standard for Discovery to January 13, 2017 filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. Ordered by Judge Gregory M. Sleet on 1/9/2017. Associated Cases: 1:16-cv-00882-GMS et al.(mdb)

2017-01-09

1

No Actions

SO ORDERED

2017-01-09

1

No Actions

NOTICE OF SERVICE of Defendant Watson Laboratories, Inc. and Actavis Pharma, Inc.'s Rule 26(a)(1) Initial Disclosures, and Disclosures under Paragraph 3 of the D. Del. Default Standard filed by Actavis Pharma, Inc., Watson Laboratories, Inc..(Keller, Karen) (Entered: 01/13/2017)

2017-01-13

1

View

NOTICE OF SERVICE of (1) Plaintiff's Disclosures Pursuant to District of Delaware Default Standard Paragraph 3 and (2) Plaintiff's Rule 26(a)(1) Initial Disclosures filed by Amgen Inc..(Blumenfeld, Jack) (Entered: 01/13/2017)

2017-01-13

1

View

~Util - Set Deadlines/Hearings AND Oral Order

2017-01-26

1

No Actions

ORAL ORDER - A Scheduling Conference is set for Thursday, February 23, 2017 at 10:00 AM (EST) in Courtroom 4A to discuss the contents of the Joint Status Report and Proposed Schedule. Ordered by Judge Gregory M. Sleet on 1/26/2017. Associated Cases: 1:16-cv-00853-GMS et al.(mdb)

2017-01-26

1

No Actions

NOTICE OF SERVICE of (1) Plaintiff's First Set of Requests to Watson for the Production of Documents and Things and (2) Plaintiff's Second Set of Requests to Watson for the Production of Documents and Things filed by Amgen Inc..(Noreika, Maryellen) (Entered: 02/03/2017)

2017-02-03

1

View

NOTICE OF SERVICE of Planitiff Amgen Inc.'s Responses and Objections to Defendants' First Requests for the Production of Documents and Things filed by Amgen Inc..(Blumenfeld, Jack) (Entered: 02/06/2017)

2017-02-06

1

View

NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions Regarding Watson filed by Amgen Inc..(Blumenfeld, Jack) (Entered: 02/10/2017)

2017-02-10

1

View

Remark

2017-02-23

1

No Actions

Minute Entry for proceedings held before Judge Gregory M. Sleet - Scheduling Conference held on 2/23/2017. Discussion regarding the schedule and issues outlined in the joint status report. The court orders that these cases are consolidated for all purposes, including trial, without prejudice. All future filings are to be made ONLY in Lead C.A. No. 16-853 (GMS). There will be no summary judgment deadlines in the schedule. The Markman Hearing (1/2 day) is set for 5/22/2017 at 9:30 AM in Courtroom 4A; the Proposed Final Pretrial Order is due by the close of business on 1/29/2018; the Final Pretrial Conference is set for 2/15/2018 at 10:00 AM in Courtroom 4A; and a 7-day Bench Trial is set for 3/5/2018 at 9:00 AM in Courtroom 4A. The parties are given leave to amend the remaining deadlines in light of the assignment of these dates, and these cases are referred to the Magistrate Judge for exploring ADR. The plaintiff shall file the amended scheduling order by 3/6/2017, in the Lead Case only. (Court Reporter Kevin Maurer.) Associated Cases: 1:16-cv-00853-GMS et al.(mdb)

2017-02-23

1

No Actions

Remark - These cases have been consolidated for all purposes. All future filings shall be made ONLY in Lead C.A. No. 16-853 (GMS) (mdb) Associated Cases: 1:16-cv-00854-GMS et al.(mdb)

2017-02-23

1

No Actions

Scheduling Conference

2017-02-23

1

No Actions

- CORRECTING ENTRY

2017-03-03

1

No Actions

CORRECTING ENTRY: The Notice of Service filed on March 2, 2017 has been removed from the docket, but remains in the Lead Case. ALL FUTURE FILINGS ARE TO BE MADE ONLY IN LEAD C.A. NO. 16-853 (GMS) Associated Cases: 1:17-cv-00113-GMS et al.(mdb)

2017-03-03

1

No Actions

ORDER REASSIGNING CASE. Case reassigned to Judge Mitchell S. Goldberg, United States District Judge, United States District Court for the Eastern District of Pennsylvania, for all further proceedings. Judge Gregory M. Sleet no longer assigned to case. Signed by Judge Leonard P. Stark on 2/6/18. Associated Cases: 1:16-cv-00853-GMS et al.(gvw) (Entered: 02/06/2018)

2018-02-06

1

View

Letter to Counsel from Judge Goldberg regarding Delaware Case Assignments. (gvw) (Entered: 08/15/2018)

2018-08-15

1

View

NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re D.I. 397 in CA No. 18-853-MSG Notice of Appeal (Federal Circuit) filed by Amgen. USCA Case Number 19-1650. Fee/IFP due on 03/28/2019. Entry of Appearance due 03/28/2019. Certificate of Interest due 03/28/2019. Docketing Statement due 03/28/2019.(nmg) (Entered: 03/14/2019)

2019-03-14

1

View

ORDER of USCA as to D.I. 453 Notice of Appeal (Federal Circuit) filed by Amgen Inc in Civil Action 16-853 MSG. Decision of USCA: The stay of Appeal No. 2019-1650 is lifted, and it and Appeal No. 2019-1770 are consolidated. One set of briefs should be filed for the two appeals. Amgens opening brief is due no later than 60 days from the date of filing of this order. (nmg) (Entered: 04/30/2019)

2019-04-29

1

View

USCA Order (Federal Circuit) Terminating Appeals 2019-1650 and 2019-1770. USCA Decision: motion to voluntarily dismiss the above-captioned appeals pursuant to Fed. R. App. P. 42(b), with each side bearing its own fees and costs is GRANTED. Order issued as a mandate on 7/9/2020. (amf) (Entered: 07/09/2020)

2020-07-09

1

View

Terminate Case - Civil

2020-09-14

1

No Actions

CASE CLOSED Associated Cases: 1:16-cv-00855-MSG, 1:17-cv-00183-MSG, 1:17-cv-00713-MSG(amf)

2020-09-14

1

No Actions

Overview

Parties

Counter Claimant

Actavis Pharma, Inc. Follow

Represented By

Watson Laboratories, Inc. Follow

Represented By

Counter Defendant

Amgen Inc. Follow

Represented By

Defendant

Actavis, Inc. Follow

Represented By

Court & Judges

Patents Involved

Docket Entries

COMPLAINT for PATENT INFRINGEMENT filed against Actavis Pharma, Inc., Actavis, Inc., Watson Laboratories, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2000856.) - filed by Amgen Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(nmg) (Entered: 09/23/2016)

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) (Entered: 09/23/2016)

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/11/2016. Date of Expiration of Patent: 9/22/2026. (nmg) (Entered: 09/23/2016)

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,375,405 B2. (nmg) (Entered: 09/23/2016)

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Amgen Inc. (nmg) (Entered: 09/23/2016)

Summons Issued with Magistrate Consent Notice attached as to Actavis Pharma, Inc., Actavis, Inc., Watson Laboratories, Inc.. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (aah)

Summons Issued

SUMMONS Returned Executed by Amgen Inc.. Actavis Pharma, Inc. served on 9/28/2016, answer due 10/19/2016. (Noreika, Maryellen) (Entered: 09/28/2016)

Case Assigned to Judge Gregory M. Sleet. Please include the initials of the Judge (GMS) after the case number on all documents filed. Associated Cases: 1:16-cv-00853-GMS, 1:16-cv-00854-GMS, 1:16-cv-00855-GMS (rjb)

Case Assigned/Reassigned

DECLARATION of Mailing (as to service on Waston Laboratories, Inc. and Actavis, Inc.) by Amgen Inc.. (Attachments: # 1 Exhibit A - D)(Noreika, Maryellen) Modified on 10/5/2016 (mdb). (Entered: 10/05/2016)

STIPULATION TO EXTEND TIME (and proposed order) to move, plead or otherwise respond to the Complaint to November 18, 2016 - filed by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Keller, Karen) (Entered: 10/18/2016)

~Util - Set/Reset Answer Deadline AND SO ORDERED

MOTION for Pro Hac Vice Appearance of Attorney John W. Bateman, C. Kyle Musgrove, and Elizabeth M. Crompton - filed by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Keller, Karen) (Entered: 10/31/2016)

SO ORDERED - re 9 MOTION for Pro Hac Vice Appearance of Attorney John W. Bateman, C. Kyle Musgrove, and Elizabeth M. Crompton filed by Actavis Pharma, Inc., Watson Laboratories, Inc. Ordered by Judge Gregory M. Sleet on 11/3/2016. (mdb)

SO ORDERED

Pro Hac Vice Attorney Elizabeth M. Crompton for Watson Laboratories, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lmm)

Add Attorneys - PHV only

MOTION for Pro Hac Vice Appearance of Attorney John D. Murnane, Joshua I. Rothman and Alicia A. Russo of FITZPATRICK, CELLA, HARPER & SCINTO - filed by Amgen Inc.. (Noreika, Maryellen) (Entered: 11/07/2016)

Pro Hac Vice Attorney John W. Bateman for Watson Laboratories, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lmm)

Add Attorneys - PHV only

MOTION for Pro Hac Vice Appearance of Attorney Lois M. Kwasigroch and Wendy A. Whiteford - filed by Amgen Inc.. (Noreika, Maryellen) (Entered: 11/09/2016)

SO ORDERED

STIPULATION of Dismissal of Actavis, Inc., Without Prejudice by Actavis Pharma, Inc., Actavis, Inc., Watson Laboratories, Inc.. (Keller, Karen) Modified on 11/15/2016 (mdb). (Entered: 11/15/2016)

Pro Hac Vice Attorney Cecil Kyle Musgrove for Watson Laboratories, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lmm)

SO ORDERED

Add Attorneys - PHV only

SO ORDERED - re 12 Stipulation of Dismissal of Actavis, Inc., Without Prejudice. Signed by Judge Gregory M. Sleet on 11/17/2016. (mdb) (Entered: 11/17/2016)

ANSWER to 1 Complaint, Counterclaims against Amgen Inc. by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Attachments: # 1 Exhibit A)(Keller, Karen) Modified on 11/18/2016 (mdb). (Entered: 11/18/2016)

ORDER REGARDING CASE MANAGEMENT IN CIVIL CASES. Signed by Judge Gregory M. Sleet on 11/18/2016. (asw) (Entered: 11/18/2016)

STIPULATION TO EXTEND TIME for the parties to submit the joint status report and proposed scheduling order to December 15, 2016 - filed by Amgen Inc.. (Blumenfeld, Jack) (Entered: 12/08/2016)

Amended ANSWER to 1 Complaint, Answer and Counterclaims 14, COUNTERCLAIM against Amgen Inc. by Actavis Pharma, Inc., Watson Laboratories, Inc.. (Attachments: # 1 Exhibit A)(Keller, Karen) (Entered: 12/09/2016)

SO ORDERED

Joint STATUS REPORT by Amgen Inc.. (Noreika, Maryellen) (Entered: 12/15/2016)

ANSWER to 18 Answer to Complaint, Counterclaim -- Plaintiff's Answer to Defendant Watson Laboratories, Inc.'s Amended Counterclaims -- by Amgen Inc..(Blumenfeld, Jack) (Entered: 12/27/2016)

NOTICE OF SERVICE of Defendants First Set of Requests for Production filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Matterer, Mary) (Entered: 01/05/2017)

STIPULATION TO EXTEND TIME to serve Initial Disclosures Puruant to Fed. R. Civ. P. 26(a) and Pursuant to Paragrah 3 of Default Standard for Discovery to January 13, 2017 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Matterer, Mary) (Entered: 01/06/2017)

NOTICE OF SERVICE of Plaintiff's Default Standard 4(a) Disclosures filed by Amgen Inc..(Blumenfeld, Jack) (Entered: 01/06/2017)

SO ORDERED

NOTICE OF SERVICE of Defendant Watson Laboratories, Inc. and Actavis Pharma, Inc.'s Rule 26(a)(1) Initial Disclosures, and Disclosures under Paragraph 3 of the D. Del. Default Standard filed by Actavis Pharma, Inc., Watson Laboratories, Inc..(Keller, Karen) (Entered: 01/13/2017)

NOTICE OF SERVICE of (1) Plaintiff's Disclosures Pursuant to District of Delaware Default Standard Paragraph 3 and (2) Plaintiff's Rule 26(a)(1) Initial Disclosures filed by Amgen Inc..(Blumenfeld, Jack) (Entered: 01/13/2017)

~Util - Set Deadlines/Hearings AND Oral Order

ORAL ORDER - A Scheduling Conference is set for Thursday, February 23, 2017 at 10:00 AM (EST) in Courtroom 4A to discuss the contents of the Joint Status Report and Proposed Schedule. Ordered by Judge Gregory M. Sleet on 1/26/2017. Associated Cases: 1:16-cv-00853-GMS et al.(mdb)

NOTICE OF SERVICE of (1) Plaintiff's First Set of Requests to Watson for the Production of Documents and Things and (2) Plaintiff's Second Set of Requests to Watson for the Production of Documents and Things filed by Amgen Inc..(Noreika, Maryellen) (Entered: 02/03/2017)

NOTICE OF SERVICE of Planitiff Amgen Inc.'s Responses and Objections to Defendants' First Requests for the Production of Documents and Things filed by Amgen Inc..(Blumenfeld, Jack) (Entered: 02/06/2017)

NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions Regarding Watson filed by Amgen Inc..(Blumenfeld, Jack) (Entered: 02/10/2017)

Remark

Remark - These cases have been consolidated for all purposes. All future filings shall be made ONLY in Lead C.A. No. 16-853 (GMS) (mdb) Associated Cases: 1:16-cv-00854-GMS et al.(mdb)

Scheduling Conference

- CORRECTING ENTRY

CORRECTING ENTRY: The Notice of Service filed on March 2, 2017 has been removed from the docket, but remains in the Lead Case. ALL FUTURE FILINGS ARE TO BE MADE ONLY IN LEAD C.A. NO. 16-853 (GMS) Associated Cases: 1:17-cv-00113-GMS et al.(mdb)

Letter to Counsel from Judge Goldberg regarding Delaware Case Assignments. (gvw) (Entered: 08/15/2018)

Terminate Case - Civil

CASE CLOSED Associated Cases: 1:16-cv-00855-MSG, 1:17-cv-00183-MSG, 1:17-cv-00713-MSG(amf)

Track Case Updates

Actavis Pharma, Inc.

Watson Laboratories, Inc.

Amgen Inc.

Actavis, Inc.